Patents by Inventor Tatiana Ort
Tatiana Ort has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141055Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: June 29, 2023Publication date: May 2, 2024Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 11732050Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: May 19, 2020Date of Patent: August 22, 2023Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20200277393Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: May 19, 2020Publication date: September 3, 2020Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 10689453Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: April 12, 2019Date of Patent: June 23, 2020Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20200010571Abstract: The present invention relates to bispecific anti-TNF-?/IL-17A antibodies and anti-TNF-? antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.Type: ApplicationFiled: September 11, 2019Publication date: January 9, 2020Inventors: Mark Chiu, Jennifer Nemeth-Seay, Tatiana Ort, Fang Shen
-
Publication number: 20190248910Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: April 12, 2019Publication date: August 15, 2019Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 10301392Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: May 16, 2017Date of Patent: May 28, 2019Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20170320957Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: May 16, 2017Publication date: November 9, 2017Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20170218092Abstract: The present invention relates to bispecific anti-TNF-?/IL-17A antibodies and anti-TNF-? antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.Type: ApplicationFiled: January 27, 2017Publication date: August 3, 2017Inventors: Mark Chiu, Jennifer Nemeth-Seay, Tatiana Ort, Fang Shen
-
Patent number: 9683046Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: July 2, 2015Date of Patent: June 20, 2017Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20150299330Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: July 2, 2015Publication date: October 22, 2015Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 9102737Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: March 15, 2013Date of Patent: August 11, 2015Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 8906649Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: GrantFiled: February 6, 2013Date of Patent: December 9, 2014Assignee: Janssen Biotech, Inc.Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
-
Publication number: 20140220634Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: ApplicationFiled: February 6, 2013Publication date: August 7, 2014Applicant: Janssen Biotech, Inc.Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
-
Publication number: 20130243795Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: JANSSEN BIOTECH, INC.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 8394378Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: GrantFiled: September 26, 2011Date of Patent: March 12, 2013Assignee: Janssen Biotech, Inc.Inventors: John Kehoe, Jennifer Lee Gardiner, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler
-
Publication number: 20130035559Abstract: The present invention provides a site specific way to enhance a natural hormonal response to nutrients entering the small intestine after gastric emptying, thereby providing therapeutic value for obesity or diabetic patients. In one aspect, the present invention provides methods of stimulating the release of satiety hormone in a subject comprising applying a first electrical stimulus to a tissue in the lumen of the gastrointestinal system of the subject contemporaneously with the contacting of L-cells of the tissue with a nutrient stimulus. The present invention also provides methods for predicting patient response to a weight loss surgery comprising applying a first electrical stimulus to a tissue of the gastrointestinal system of said patient contemporaneously with the contacting of L-cells of the tissue with a nutrient stimulus, assessing the effect of the electrical stimulus in said patient, and, correlating said effect to said patient's response to a weight loss surgery.Type: ApplicationFiled: May 4, 2012Publication date: February 7, 2013Inventors: Pamela J. Hornby, Tatiana Ort, Radhika Kajekar, Paul R. Wade
-
Publication number: 20120108795Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: ApplicationFiled: September 26, 2011Publication date: May 3, 2012Inventors: John Kehoe, Jennifer Lee Gardiner, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler
-
Publication number: 20110071277Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.Type: ApplicationFiled: March 12, 2010Publication date: March 24, 2011Inventors: Simon Blake, Jill Carton, Jennifer Henrica Lee, Keying Ma, Paul Marsters, Kristen Picha, Xiao-Yu R. Song, Francis Farrell, Lynne Murray, Alexey Teplyakov, Tatiana Ort
-
Publication number: 20100056948Abstract: The present invention provides, among other things, a site specific way to enhance a natural hormonal response to nutrients entering the small intestine after gastric emptying, thereby providing therapeutic value for obesity or diabetic patients. In one aspect, the present invention provides methods of stimulating the release of satiety hormone in a subject comprising applying a first electrical stimulus to a tissue in the lumen of the gastrointestinal system of the subject contemporaneously with the contacting of L-cells of the tissue with a nutrient stimulus.Type: ApplicationFiled: August 25, 2009Publication date: March 4, 2010Inventors: Pamela J. Hornby, Tatiana Ort, Radhika Kajekar, Paul R. Wade